Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53

(2018) Bin Jiang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Association between mutant IDHs and tumorigenesis in gliomas

(2018) Shigeo Ohba et al.   Medical Molecular Morphology

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases

(2018) Hani M. Babiker et al.   INVESTIGATIONAL NEW DRUGS

BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas

(2018) Laura Frazão et al.   BMC CANCER

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures

(2017) Adrienne Johnson et al.   ONCOLOGIST

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma

(2016) Michael G Ozawa et al.   MODERN PATHOLOGY

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis

(2016) T.-C. A. Johannessen et al.   MOLECULAR CANCER RESEARCH

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies

(2016) Sarah T. Garber et al.   NEURO-ONCOLOGY

Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes

(2016) C. Mårten Lindqvist et al.   Oncotarget

PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations

(2016) Andreas H. Scheel et al.   OncoImmunology

TP53: an oncogene in disguise

(2015) T Soussi et al.   CELL DEATH AND DIFFERENTIATION

High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan

(2015) Nisreen Amayiri et al.   INTERNATIONAL JOURNAL OF CANCER

CDKN2ALoss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas

(2015) Gerald F. Reis et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

(2015) Jean Jacques Grob et al.   LANCET ONCOLOGY

Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers

(2015) Adam Shlien et al.   NATURE GENETICS

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

H3F3A K27M Mutation in Pediatric CNS Tumors

(2013) Gerrit H. Gielen et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide

(2013) Xiang Wang et al.   ANNALS OF SURGICAL ONCOLOGY

Regulation of angiogenesis by PI3K signaling networks

(2013) Mariona Graupera et al.   EXPERIMENTAL CELL RESEARCH

Histone Acetyltransferase 1 Promotes Homologous Recombination in DNA Repair by Facilitating Histone Turnover

(2013) Xiaohan Yang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

BRAF inhibitors in cancer therapy

(2013) Carolina Hertzman Johansson et al.   PHARMACOLOGY & THERAPEUTICS

ToBRAFor Not toBRAF: Is That Even a Question Anymore?

(2012) Craig Horbinski   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

The RAG1 V(D)J recombinase/ubiquitin ligase promotes ubiquitylation of acetylated, phosphorylated histone 3.3

(2011) Jessica M. Jones et al.   IMMUNOLOGY LETTERS

Whole-exome sequencing of pediatric acute lymphoblastic leukemia

(2011) H Lilljebjörn et al.   LEUKEMIA

Challenging issues in pediatric oncology

(2011) Ching-Hon Pui et al.   Nature Reviews Clinical Oncology

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

(2009) S. Yip et al.   CLINICAL CANCER RESEARCH

The cancer genome

(2009) Michael R. Stratton et al.   NATURE

Clinical Outcomes and Correlates of TP53 Mutations and Cancer

(2009) A. I. Robles et al.   Cold Spring Harbor Perspectives in Biology